| Generic Name | Brand Name |
|---|---|
| raltegravir | Isentress |
Raltegravir is available as pills. Usually, a pill is taken twice a day.
Raltegravir blocks the HIV integrase enzyme. This prevents HIV from multiplying. When the amount of virus in the blood is kept at a minimum, the immune system has a chance to recover and grow stronger.
Raltegravir is used in combination with other antiretroviral medicines to treat HIV. It helps prevent the virus from spreading in the body and helps reduce the amount of virus in your blood (viral load). Raltegravir may be effective for people who have taken other anti-HIV drugs without success.
The use of three or more antiretroviral medicines (highly active antiretroviral therapy, or HAART) is the usual treatment for HIV infection.
The combination of medicines used for HAART will depend on your health, other conditions you might have (such as hepatitis), and results of testing. Talk to your doctor about the best treatment plan for you.
Treatment guidelines suggest the following for people with HIV:1, 2, 3
You may also want to start HIV treatment if your sexual partner does not have HIV. Treatment of your HIV infection can help prevent the spread of HIV to your sexual partner.3
Raltegravir works well with other antiretroviral medicines to improve CD4+ cell counts and reduce viral load.4, 5
The most common side effects of raltegravir include diarrhea, nausea, headache, and fever.
See Drug Reference for a full list of side effects. (Drug Reference is not available in all systems.)
Raltegravir should be used to treat a pregnant woman only if the potential benefit is greater than the risk to the developing baby (fetus).
Complete the new medication information form (PDF)(What is a PDF document?) to help you understand this medication.
Citations
- U.S. Department of Health and Human Services (2009). Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Available online: http://www.aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf.
- Hammer, Scott M, et al. (2008). Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society USA Panel. JAMA, 300 (5): 555–570.
- U.S. Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents (2011). Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Available online: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf.
- Steigbigel RT, et al. (2008). Raltegravir with optimized background therapy for resistant HIV-1 infection. New England Journal of Medicine, 359(4): 339–354.
- Cooper DA, et al. (2008). Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. New England Journal of Medicine, 359(4): 355–365.
Last Revised: October 17, 2011
Author: Healthwise Staff
Medical Review: Caroline S. Rhoads, MD - Internal Medicine & Peter Shalit, MD, PhD - Internal Medicine
This information does not replace the advice of a doctor. Healthwise, Incorporated disclaims any warranty or liability for your use of this information. Your use of this information means that you agree to the Terms of Use. How this information was developed to help you make better health decisions.
To learn more visit Healthwise.org
© 1995-2012 Healthwise, Incorporated. Healthwise, Healthwise for every health decision, and the Healthwise logo are trademarks of Healthwise, Incorporated.
Seton is proud to have four hospitals – the only hospitals in Central Texas - that have earned the Magnet designation, the highest award for nursing excellence given by the American Nurses Association.
